JP2008517984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517984A5 JP2008517984A5 JP2007538500A JP2007538500A JP2008517984A5 JP 2008517984 A5 JP2008517984 A5 JP 2008517984A5 JP 2007538500 A JP2007538500 A JP 2007538500A JP 2007538500 A JP2007538500 A JP 2007538500A JP 2008517984 A5 JP2008517984 A5 JP 2008517984A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- hydrocarbyl
- hydroxy
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 60
- 239000001257 hydrogen Substances 0.000 claims 60
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 58
- 125000001424 substituent group Chemical group 0.000 claims 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 47
- -1 hydroxy, cyano, amino, methylamino, dimethylamino Chemical group 0.000 claims 46
- 229910052760 oxygen Inorganic materials 0.000 claims 46
- 125000004432 carbon atom Chemical group C* 0.000 claims 45
- 229910052757 nitrogen Inorganic materials 0.000 claims 35
- 125000000623 heterocyclic group Chemical group 0.000 claims 34
- 229910052736 halogen Inorganic materials 0.000 claims 33
- 150000002367 halogens Chemical class 0.000 claims 33
- 150000002431 hydrogen Chemical group 0.000 claims 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 229910052731 fluorine Inorganic materials 0.000 claims 26
- 239000011737 fluorine Substances 0.000 claims 26
- 229910052717 sulfur Inorganic materials 0.000 claims 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 25
- 125000005647 linker group Chemical group 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 23
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 16
- 229910052801 chlorine Inorganic materials 0.000 claims 16
- 239000000460 chlorine Substances 0.000 claims 16
- 125000002837 carbocyclic group Chemical group 0.000 claims 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 13
- 125000002252 acyl group Chemical group 0.000 claims 11
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 10
- 229910052794 bromium Inorganic materials 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 10
- 125000004423 acyloxy group Chemical group 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 3
- 108091008611 Protein Kinase B Proteins 0.000 claims 3
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 241001553014 Myrsine salicina Species 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000005621 boronate group Chemical group 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- YOIAWAIKYVEKMF-UHFFFAOYSA-N trifluoromethanesulfonic acid Chemical group OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F YOIAWAIKYVEKMF-UHFFFAOYSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62182104P | 2004-10-25 | 2004-10-25 | |
| GB0423655A GB0423655D0 (en) | 2004-10-25 | 2004-10-25 | Pharmaceutical compounds |
| GB0423655.0 | 2004-10-25 | ||
| US60/621,821 | 2004-10-25 | ||
| US68411905P | 2005-05-24 | 2005-05-24 | |
| US60/684,119 | 2005-05-24 | ||
| PCT/GB2005/004119 WO2006046024A1 (en) | 2004-10-25 | 2005-10-25 | Ortho- condensed pyridine and pyrimidine derivatives (e. g. purines) as protein kinases inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008517984A JP2008517984A (ja) | 2008-05-29 |
| JP2008517984A5 true JP2008517984A5 (enExample) | 2008-12-18 |
| JP5128284B2 JP5128284B2 (ja) | 2013-01-23 |
Family
ID=35715573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538500A Expired - Lifetime JP5128284B2 (ja) | 2004-10-25 | 2005-10-25 | プロテインキナーゼ阻害剤としてのオルト縮合ピリジンおよびピリミジン誘導体（例えばプリン類） |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8546407B2 (enExample) |
| EP (2) | EP2272517B2 (enExample) |
| JP (1) | JP5128284B2 (enExample) |
| AR (1) | AR051342A1 (enExample) |
| AT (1) | ATE513549T1 (enExample) |
| CY (1) | CY1115946T1 (enExample) |
| DK (1) | DK2272517T4 (enExample) |
| ES (1) | ES2523266T5 (enExample) |
| MY (1) | MY179032A (enExample) |
| PL (1) | PL2272517T5 (enExample) |
| PT (1) | PT2272517E (enExample) |
| SI (1) | SI2272517T2 (enExample) |
| UY (1) | UY29176A1 (enExample) |
| WO (1) | WO2006046024A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US8921376B2 (en) * | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
| DE102005037733A1 (de) * | 2005-08-10 | 2007-02-15 | Merck Patent Gmbh | Adeninderivate |
| WO2007038215A1 (en) | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| ATE525374T1 (de) | 2005-12-13 | 2011-10-15 | Incyte Corp | Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren |
| WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009536620A (ja) * | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| DK3421471T3 (da) * | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| EP2029592A1 (en) * | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2008012635A2 (en) * | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| PT2583970E (pt) | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AU2007283401A1 (en) * | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| AR064415A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| JP5492565B2 (ja) | 2006-12-22 | 2014-05-14 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼ阻害剤としての置換複素環 |
| EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| WO2008133975A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| ES2467665T5 (es) | 2007-06-13 | 2022-11-03 | Incyte Holdings Corp | Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| US8247410B2 (en) * | 2007-10-05 | 2012-08-21 | Verastem | Pyrimidine substituted purine derivatives |
| PT2201012E (pt) | 2007-10-11 | 2014-09-04 | Astrazeneca Ab | Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b |
| SG191660A1 (en) | 2008-03-11 | 2013-07-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| MX2010011450A (es) | 2008-04-21 | 2010-11-10 | Lexicon Pharmaceuticals Inc | Inhibidores del limk2, composiciones que los comprenden y metodos para su uso. |
| EP2355821A1 (en) | 2008-11-11 | 2011-08-17 | Eli Lilly and Company | P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| JP6172939B2 (ja) | 2009-05-22 | 2017-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR101805936B1 (ko) | 2009-10-09 | 2017-12-07 | 인사이트 홀딩스 코포레이션 | 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| KR101398268B1 (ko) | 2009-10-23 | 2014-05-23 | 일라이 릴리 앤드 캄파니 | Ａｋｔ 억제제 |
| EP3444242A3 (en) | 2009-11-05 | 2019-03-20 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 저해제에 대한 국소 제형 |
| ES2664801T3 (es) * | 2010-09-17 | 2018-04-23 | Mallinckrodt Llc | Proceso mejorado para la preparación de un precursor de sufentanilo base |
| EA026201B1 (ru) | 2010-11-19 | 2017-03-31 | Инсайт Холдингс Корпорейшн | Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| CN103732226B (zh) | 2011-02-18 | 2016-01-06 | 诺瓦提斯药物公司 | mTOR/JAK抑制剂组合疗法 |
| HRP20191927T1 (hr) | 2011-04-01 | 2020-01-10 | Astrazeneca Ab | Terapijsko liječenje |
| PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| EA201791043A1 (ru) | 2011-07-13 | 2017-09-29 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| PL2785349T5 (pl) | 2011-11-30 | 2023-01-30 | Astrazeneca Ab | Kombinacja do leczenia nowotworu |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| HRP20171610T1 (hr) | 2012-07-04 | 2018-03-23 | Rhizen Pharmaceuticals S.A. | Selektivni inhibitori pi3k delta |
| RS62329B1 (sr) | 2012-11-15 | 2021-10-29 | Incyte Holdings Corp | Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja |
| TR201820520T4 (tr) | 2013-03-06 | 2019-01-21 | Incyte Holdings Corp | Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler. |
| DK3030227T3 (da) | 2013-08-07 | 2020-04-20 | Incyte Corp | Vedvarende frigivelses-doseringsformer for en jak1-inhibitor |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| BR112017028448A2 (pt) | 2015-07-02 | 2018-08-28 | Horizon Orphan Llc | análogos de cisteamina resistentes a ado e usos dos mesmos |
| TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
| US10387298B2 (en) | 2017-04-04 | 2019-08-20 | Hailo Technologies Ltd | Artificial neural network incorporating emphasis and focus techniques |
| US11544545B2 (en) | 2017-04-04 | 2023-01-03 | Hailo Technologies Ltd. | Structured activation based sparsity in an artificial neural network |
| US11615297B2 (en) | 2017-04-04 | 2023-03-28 | Hailo Technologies Ltd. | Structured weight based sparsity in an artificial neural network compiler |
| US12430543B2 (en) | 2017-04-04 | 2025-09-30 | Hailo Technologies Ltd. | Structured sparsity guided training in an artificial neural network |
| US11238334B2 (en) | 2017-04-04 | 2022-02-01 | Hailo Technologies Ltd. | System and method of input alignment for efficient vector operations in an artificial neural network |
| US11551028B2 (en) | 2017-04-04 | 2023-01-10 | Hailo Technologies Ltd. | Structured weight based sparsity in an artificial neural network |
| US11236086B2 (en) | 2017-10-18 | 2022-02-01 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| WO2021102258A1 (en) | 2019-11-22 | 2021-05-27 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| ES2177925T3 (es) * | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
| CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
| US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| DE69830409T2 (de) | 1997-08-05 | 2006-01-26 | Pfizer Products Inc., Groton | 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| YU76100A (sh) | 1998-06-02 | 2003-12-31 | Osi Pharmaceuticals Inc. | Pirolo(2,3-d) pirimidin preparati i njihova primena |
| CN1332743A (zh) | 1998-06-04 | 2002-01-23 | 艾博特公司 | 抑制细胞粘附抗炎化合物 |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO1999065908A1 (en) | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| ATE299881T1 (de) * | 1999-12-21 | 2005-08-15 | Sugen Inc | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| AU2001293788B2 (en) | 2000-08-31 | 2007-10-11 | F. Hoffmann-La Roche Ag | Quinazoline derivatives as alpha-1 adrenergic antagonists |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| MXPA03004717A (es) | 2000-12-01 | 2004-06-30 | Osi Pharm Inc | Compuestos especificos para el receptor a1, a2 y a3 de adenosina y usos de los mismos. |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| DK1474425T3 (da) | 2002-01-07 | 2006-09-25 | Eisai Co Ltd | Deazapuriner og anvendelser deraf |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| WO2004002531A1 (ja) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 血管の収縮または拡張による疾患治療剤 |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| CA2505529C (en) | 2002-11-08 | 2013-12-24 | President And Fellows Of Harvard College | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| JP4279784B2 (ja) | 2002-12-04 | 2009-06-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | １，３−ジヒドロ−イミダゾール縮合環化合物 |
| EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| SE0300457D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| JP2006517918A (ja) | 2003-04-21 | 2006-08-03 | ウスタブ オルガニケ ケミエ ア ビオケミエ ア カデミエ ベド チェスケ レプブリキ | （プリン−６−イル）アミノ酸およびその製造方法 |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| CN102786482A (zh) | 2003-11-21 | 2012-11-21 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
| JP4792974B2 (ja) * | 2003-12-25 | 2011-10-12 | 小野薬品工業株式会社 | アゼチジン環化合物およびその医薬 |
| US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| WO2007125320A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| EP2029592A1 (en) | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP2009536161A (ja) | 2006-04-25 | 2009-10-08 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| PT2201012E (pt) | 2007-10-11 | 2014-09-04 | Astrazeneca Ab | Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b |
-
2005
- 2005-10-21 MY MYPI20054963A patent/MY179032A/en unknown
- 2005-10-24 UY UY29176A patent/UY29176A1/es not_active IP Right Cessation
- 2005-10-25 DK DK10184485.0T patent/DK2272517T4/da active
- 2005-10-25 SI SI200531910T patent/SI2272517T2/sl unknown
- 2005-10-25 WO PCT/GB2005/004119 patent/WO2006046024A1/en not_active Ceased
- 2005-10-25 EP EP10184485.0A patent/EP2272517B2/en not_active Expired - Lifetime
- 2005-10-25 ES ES10184485.0T patent/ES2523266T5/es not_active Expired - Lifetime
- 2005-10-25 PL PL10184485T patent/PL2272517T5/pl unknown
- 2005-10-25 PT PT101844850T patent/PT2272517E/pt unknown
- 2005-10-25 AT AT05797685T patent/ATE513549T1/de not_active IP Right Cessation
- 2005-10-25 AR ARP050104467 patent/AR051342A1/es active IP Right Grant
- 2005-10-25 EP EP20050797685 patent/EP1812004B1/en not_active Expired - Lifetime
- 2005-10-25 US US11/577,963 patent/US8546407B2/en active Active
- 2005-10-25 JP JP2007538500A patent/JP5128284B2/ja not_active Expired - Lifetime
-
2013
- 2013-09-04 US US14/017,814 patent/US8809336B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/310,475 patent/US9006430B2/en not_active Expired - Lifetime
- 2014-11-27 CY CY20141100991T patent/CY1115946T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517984A5 (enExample) | ||
| JP6805220B2 (ja) | 治療上活性な化合物およびそれらの使用方法 | |
| US10000486B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JP6632746B2 (ja) | 癌を治療するための１−テトラヒドロピラニルカルボニル−２，３−ジヒドロ−１ｈ−インドール化合物 | |
| EP2262808B1 (en) | Chemokine receptor modulators | |
| JP2009536620A5 (enExample) | ||
| CA2422354A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| TW201024313A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| CA3116769A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| JP2008517983A5 (enExample) | ||
| ES2991981T3 (es) | Inhibidor de la interacción proteína-proteína de MLL1-WDR5 de feniltriazol | |
| JP2012517428A5 (enExample) | ||
| WO2013192049A2 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| CA3021675C (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| CA3148211A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| CA2626402A1 (en) | Potassium channel inhibitors | |
| US10385056B2 (en) | 4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof | |
| CN103025722B (zh) | 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性 | |
| CA3055509A1 (en) | Novel benzimidazolone compound and pharmaceutical use thereof | |
| ES2894657T3 (es) | Compuestos de etinilo, su preparación y su uso terapéutico para el tratamiento de la malaria | |
| KR20250138280A (ko) | 조작된 단백질의 선택적 분해를 위한 화합물 및 조성물 | |
| WO2024158759A2 (en) | Inhibitors of solvent front mutated ret kinase | |
| EP4067354A1 (en) | Novel triazolopyridine derivative and pharmaceutical composition comprising same |